Ipsen open to more M&A which follows Merrimack model, says Alexandre Lebeaut

1 February 2017

French pharma group Ipsen’s (Euronext: IPN) acquisition of the oncology assets of Merrimack Pharmaceuticals (Nasdaq: MACK), which was announced in the first working week of 2017, was potentially evidence not just of a busy year to come in mergers and acquisitions (M&A) for the pharma sector.

It also signaled that more acquisitions are likely to follow in the near future for Ipsen itself, if the words of its chief scientific officer Alexandre Lebeaut are anything to go by.

"We are certainly very open to acquire externally-borne innovation, it’s part of our model"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK